Johnson & Johnson released its fourth quarter and full-year financial results for 2017.
Here are five things to know:
1. Within the orthopedics segment, J&J reported $2.34 billion in fourth quarter sales, a 2 percent drop compared to fourth quarter sales in 2016.
2. J&J’s orthopedic segment also saw a dip in 2017 full-year sales from $9.33 billion in 2016 to $9.25 billion in 2017. This represents a 0.8 percent decline.
3. U.S. orthopedic sales dropped 2.3 percent in the fourth quarter, totaling $1.38 billion. International sales also decreased from $965 million in 2016 to $950 million in the fourth quarter of 2017.
4. Concerning the company's orthopedic medical devices, J&J's hip and trauma lines were the only two segments to experience year-over-year growth. The hip line grew 2.4 percent to $1.39 billion while the
trauma line grew 1.8 percent to $2.61 billion.
5. In the fourth quarter, J&J reported major declines to its spine business line. For the year-end, the company reported a 4 percent drop in sales to $3.72 billion.